Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal

Feb 15, 2019

|

NEW YORK (GenomeWeb) — Decipher Biosciences — formerly GenomeDx Biosciences — announced today that it has signed an agreement to help Dendreon Pharmaceuticals identify patients who are likely to respond to its prostate cancer therapy Provenge (sipuleucel-T).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal

To read the full story....

Breaking News

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Promega to Develop MSI Assay as CDx for Incyte Endometrial Cancer Drug

Genosity Inks Comarketing Agreement with Personal Genome Diagnostics

JP Morgan Downgrades Illumina to Neutral on Grail Deal

Ortho Clinical Diagnostics Nabs $12.9M BARDA Award for SARS-CoV-2 Antigen, Antibody Tests

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

Illumina to Acquire Grail for $8B in Cash and Stock

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Sponsorships